- Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ:VTRS) biosimilars assets for up to $3.335 billion in stock and cash.
- The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1 billion.
- Viatris will also pay $50 million to Biocon Biologics to fund certain capital expenditures.
- Biocon Biologics will gain access to Viatris' global biosimilars business, expected to see $1 billion in revenues next year.
- Related: India's Biocon Mulls Merger Of Biosimilar Business With Mylan: Moneycontrol.
- Shaw will continue in her current position. Viatris will designate Rajiv Malik, President of Viatris, to serve on Biocon Biologics's board.
- Viatris Earnings: The Company reported Q4 FY21 sales of $4.33 billion, +21% Y/Y, slightly below the consensus of $4.35 billion.
- It reported a narrower EPS loss of $(0.22) compared to $(1.07) a year ago.
- Guidance: Viatris expects FY22 sales of $17 billion - $17.5 billion, compared to the consensus of $17.88 billion.
- It forecasts adjusted EBITDA of $5.8 billion - $6.2 billion and free cash flow of $2.5 billion - $2.9 billion.
- Price Action: VTRS shares are down 3.51% at $14.03 during the premarket session on Monday's last check.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks